会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Substituted propane-phosphinic acid compounds
    • 取代的丙烷 - 次膦酸化合物
    • US5190933A
    • 1993-03-02
    • US845871
    • 1992-03-03
    • Eric K. BaylisLudwig MaierStuart J. MickelHans-Rudolf OlpeHelmut BittigerWolfgang FrostlRoger G. Hall
    • Eric K. BaylisLudwig MaierStuart J. MickelHans-Rudolf OlpeHelmut BittigerWolfgang FrostlRoger G. Hall
    • C07F9/30C07F9/48
    • C07F9/48C07F9/301Y02P20/55
    • Compounds of the formula I ##STR1## wherein R denotes an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic or araliphatic radical having 2 or more carbon atoms, and wherein one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen or an aliphatic, cycloaliphatic, araliphatic or aromatic radical, another one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen or, in the case of R.sup.1 and R.sup.2, is hydroxy, and the remaining one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen, or wherein R denotes methyl, R.sub.1 denotes hydrogen or hydroxy, R.sub.2 denotes an aromatic radical and R.sub.3 represents hydrogen, and their salts have GABA.sub.B -antagonistic properties and can be used as GABA.sub.B -antagonists. They are obtained when in a compound of formula II ##STR2## in which R, R.sup.1, R.sup.2 and R.sup.3 have their previous significances, Z represents --NH.sub.2 and R.sup.4 denotes a hydroxy-protective group R.sup.5 or, when R.sup.1 and R.sup.3 denote hydrogen and R.sup.2 denotes hydrogen or alkyl, denotes an alkali metal or ammonium ion R.sup.6, or Z represents a protected or latent amino group Z.sup.o and R.sup.4 denotes hydrogen or a hydroxy-protective group R.sup.5, any group R.sup.5 or R.sup.6 is replaced by hydrogen, and/or any group Z.sup.o is converted into --NH.sub.2.
    • 式I的化合物(I)其中R表示具有2个或更多个碳原子的脂族,脂环族,脂环族 - 脂族或芳脂族基团,其中R1,R2和R3中的一个表示氢或脂族,脂环族 ,芳脂族或芳族基团,R 1,R 2和R 3中的另一个为氢,或在R 1和R 2的情况下为羟基,其余的R 1,R 2和R 3为氢,或其中R为甲基,R 1为 氢或羟基,R 2表示芳族基团,R 3表示氢,并且它们的盐具有GABAB拮抗性质,可用作GABAB-拮抗剂。 当其中R,R 1,R 2和R 3具有其先前含义的式II化合物(II)时,它们是得到的,Z表示-NH 2,R4表示羟基保护基R5,或者当R1和R3表示 氢和R2表示氢或烷基,表示碱金属或铵离子R6,或Z表示保护或潜在氨基Zo,R4表示氢或羟基保护基R5,任何基团R5或R6被氢代替,以及 /或任何基团Zo被转化为-NH 2。
    • 3. 发明授权
    • Substituted propane-phosphinic acid compounds
    • 取代的丙烷 - 次膦酸化合物
    • US5300679A
    • 1994-04-05
    • US968101
    • 1992-10-29
    • Eric K. BaylisHelmut BittigerWolfgang FrostlRoger G. HallLudwig MaierStuart J. MickelHans-Rudolf Olpe
    • Eric K. BaylisHelmut BittigerWolfgang FrostlRoger G. HallLudwig MaierStuart J. MickelHans-Rudolf Olpe
    • C07F9/30C07F9/48A61K31/13A61K31/185
    • C07F9/301C07F9/48Y02P20/55
    • Compounds of the formula I ##STR1## wherein R denotes an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic or araliphatic radical having 2 or more carbon atoms, and wherein one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen or an aliphatic, cycloaliphatic, araliphatic or aromatic radical, another one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen or, in the case of R.sup.1 and R.sup.2, is hydroxy, and the remaining one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen, or wherein R denotes methyl, R.sub.1 denotes hydrogen or hydroxy, R.sub.2 denotes an aromatic radical and R.sub.3 represents hydrogen, and their salts have GABA.sub.B -antagonistic properties and can be used as GABA.sub.B -antagonists. They are obtained when in a compound of formula II ##STR2## in which R, R.sup.1, R.sup.2 and R.sup.3 have their previous significances, Z represents --NH.sub.2 and R.sup.4 denotes a hydroxy-protective group R.sup.5 or, when R.sup.1 and R.sup.3 denote hydrogen and R.sup.2 denotes hydrogen or alkyl, denotes an alkali metal or ammonium ion R.sup.6, or Z represents a protected or latent amino group Z.sup.o and R.sup.4 denotes hydrogen or a hydroxy-protective group R.sup.5, any group R.sup.5 or R.sup.6 is replaced by hydrogen, and/or any group Z.sup.o is converted into --NH.sub.2.
    • 式I的化合物(I)其中R表示具有2个或更多个碳原子的脂族,脂环族,脂环族 - 脂族或芳脂族基团,其中R1,R2和R3中的一个表示氢或脂族,脂环族 ,芳脂族或芳族基团,R 1,R 2和R 3中的另一个为氢,或在R 1和R 2的情况下为羟基,其余的R 1,R 2和R 3为氢,或其中R为甲基,R 1为 氢或羟基,R 2表示芳族基团,R 3表示氢,并且它们的盐具有GABAB拮抗性质,可用作GABAB-拮抗剂。 当其中R,R 1,R 2和R 3具有其先前含义的式II化合物(II)时,它们是得到的,Z表示-NH 2,R4表示羟基保护基R5,或者当R1和R3表示 氢和R2表示氢或烷基,表示碱金属或铵离子R6,或Z表示保护或潜在氨基Zo,R4表示氢或羟基保护基R5,任何基团R5或R6被氢代替,以及 /或任何基团Zo被转化为-NH 2。
    • 9. 发明授权
    • Chemical process for the production of .alpha.-aminophosphonic acids and
peptide derivatives
    • 用于生产α-氨基膦酸和肽衍生物的化学方法
    • US4331591A
    • 1982-05-25
    • US080763
    • 1979-10-01
    • Eric K. Baylis
    • Eric K. Baylis
    • A01N57/18A61K31/66A61P31/04C07F9/38C07F9/547C07K5/04C07K5/08C07C103/52C07C9/02C07G7/00
    • C07F9/3808C07K5/0827Y02P20/55
    • The present invention provides a process for the production of physiologically-useful .alpha.-aminophosphonic acids and peptide derivatives of the formula: ##STR1## wherein R and R.sub.1 may be the same or different and each can be hydrogen, deuterium or an optionally substituted lower alkyl group, lower alkenyl, lower alkynyl, cycloalkyl, aryl or heterocyclic radical containing one or more oxygen, nitrogen or sulphur atoms and which may be fused to an aromatic ring, a lower alkyl group substituted by a cycloalkyl radical, a lower alkyl group substituted by an aryl radical, a lower alkyl group substituted by a heterocyclic radical as defined above or R and R.sub.1 together form a polymethylene chain optionally interrupted by an oxygen, nitrogen or sulphur atom, or R.sub.1 represents, together with the C(R)--N
    • 本发明提供了一种制备下式的生理有用的α-氨基膦酸和肽衍生物的方法:其中R和R 1可以相同或不同,并且各自可以是氢,氘或任选取代的低级 烷基,低级烯基,低级炔基,环烷基,芳基或杂环基,其含有一个或多个氧,氮或硫原子,并且可以与芳环稠合,被环烷基取代的低级烷基,低级烷基取代 通过芳基,被如上定义的杂环基取代的低级烷基或R和R 1一起形成任选被氧,氮或硫原子间隔的聚亚甲基链,或者R 1与C(R)-N 它所连接的残基,完成杂环基团所需的原子; 并且R 2可以是氢,任选取代的被环烷基取代的低级烷基,环烷基,芳基或低级烷基,被含有一个或多个氮原子的杂环基取代的低级烷基; 通过含有一个或多个氮原子的杂环基团,或其与连接的C(H)-N残基一起可以表示完成杂环基团所需的原子; 且n为0,1,2,3或4; 包括使用氧化剂氧化具有下式的化合物:其中R,R 1,R 2和n具有其先前的含义,Z是H或通常用于氨基的保护基; 然后移除任何保护基团。
    • 10. 发明授权
    • Nucleoside phosphinate compounds and compositions
    • 核苷次膦酸盐化合物和组合物
    • US5508270A
    • 1996-04-16
    • US203962
    • 1994-02-28
    • Anthony D. BaxterEric K. BaylisStephen P. CollingwoodRoger J. TaylorAlain MesmaekerChantal Schmit
    • Anthony D. BaxterEric K. BaylisStephen P. CollingwoodRoger J. TaylorAlain MesmaekerChantal Schmit
    • C07H9/04C07F9/30C07H13/06C07H19/06C07H19/10C07H19/16C07H19/20C07H21/00A61K31/70
    • C07H19/10C07H19/20C07H21/00Y02P20/55
    • A compound of formula ##STR1## where R.sup.1 is hydrogen or a protecting group Q;R.sup.2 is hydrogen, a C.sub.1 -C.sub.8 aliphatic radical, a C.sub.6 -C.sub.15 aromatic radical, a C.sub.3 -C.sub.8 cycloaliphatic radical, a C.sub.7 -C.sub.13 araliphatic radical, an alkali metal ion or an ammonium ion;R.sup.3 and R.sup.4 are independently hydrogen, halogen or hydroxy;R.sup.5 is C.sub.6 -C.sub.10 aryloxythiocarbonyloxy, the C.sub.6 -C.sub.10 aryl group being unsubstituted or substituted, or R.sup.5.sub.a ;R.sup.5.sub.a is hydrogen, fluorine, chlorine, hydroxy, --OR.sup.8, --OCOR.sup.8 or silyloxy substituted by three C.sub.1 -C.sub.15 hydrocarbyl groups;R.sup.6 is hydrogen, a C.sub.1 -C.sub.10 aliphatic radical, a C.sub.6 -C.sub.15 aromatic radical, a C.sub.7 -C.sub.16 araliphatic radical, --COR.sup.9, --SO.sub.2 R.sup.9 or silyl substituted by three C.sub.1 -C.sub.15 hydrocarbyl groups;R.sup.7 is a monovalent nucleoside base radical, hydroxyl, --OR.sup.8 or --OCOR.sup.8, andR.sup.9 are independently a C.sub.1 -C.sub.10 aliphatic radical, a C.sub.3 -C.sub.8 cycloaliphatic radical, a C.sub.6 -C.sub.15 aromatic radical or a C.sub.7 -C.sub.16 araliphatic radical; orR.sup.5 and the indicated R.sup.6 O-together denote an isopropylidenedioxy group or R.sup.5 and R.sup.7 together denote an isopropylidenedioxy group, provided that when R.sup.5 and R.sup.7 together denote isopropylidenedioxy, R.sup.1 R.sup.2, R.sup.3 R.sup.4 and R.sup.6 are not all hydrogen. The disclosure further relates to a method of preparing the compounds of formula I by reacting a olefinic acetonide with a phosphinate compound and to the use of the compounds of formula I as pharmaceutical agents.
    • 式Ⅰ的化合物,其中R 1是氢或保护基团Q; R2是氢,C1-C8脂族基团,C6-C15芳族基团,C3-C8脂环族基团,C7-C13芳脂族基团,碱金属离子或铵离子; R3和R4独立地是氢,卤素或羟基; R5是C6-C10芳氧基硫代羰氧基,C6-C10芳基是未取代或取代的,或R5a; R5a是氢,氟,氯,羟基,-OR8,-OCOR8或被三个C1-C15烃基取代的甲硅烷氧基; R 6是氢,C 1 -C 10脂族基,C 6 -C 15芳基,C 7 -C 16芳脂基,-COR 9,-SO 2 R 9或被三个C 1 -C 15烃基取代的甲硅烷基; R7是单价核苷碱基,羟基-OR8或-OCOR8,R9独立地是C1-C10脂族基团,C3-C8脂环族基团,C6-C15芳族基团或C7-C16芳脂族基团; 或R5和所示的R6O一起表示异丙烯二氧基,或者R 5和R 7一起表示异亚丙二氧基,条件是当R 5和R 7一起表示异亚丙二氧基时,R 1 R 2,R 3 R 4和R 6不全为氢。 本公开还涉及通过使烯属丙烯腈与次膦酸盐化合物反应制备式I化合物的方法,以及式I化合物作为药剂的用途。